177Lu-DOTA-EB-TATE for Neuroendocrine Tumors
Study Summary
This trial is to test a new treatment for a rare cancer. It will study how well the treatment works and what side effects it may have.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
To what degree is 177Lu-DOTA-EB-TATE hazardous to human health?
"Owing to the data collected during Phase 1, our team at Power has assigned a score of 1 for 177Lu-DOTA-EB-TATE's safety rating. This indicates that there is limited evidence attesting to its efficacy and security."
How many participants are enrolled in this experimental research?
"Affirmative. According to the information available on clinicaltrials.gov, this medical investigation is actively recruiting patients and has been since its initial posting date of June 18th 2022. 9 applicants are required from 1 location for the successful completion of this trial."
Are enrollees still being accepted into this research trial?
"Affirmative. According to the information published on clinicaltrials.gov, this trial initially posted on June 18th 2022 is currently recruiting participants. A total of 9 participants need to be enrolled from 1 medical site."